On the Record · Zoetis
Zoetis acquisitions, on the record
The businesses Zoetis bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Abaxis, Inc.Word for word“Zoetis enhanced the portfolio of its diagnostic products with the acquisition in 2018 of Abaxis, Inc. (Abaxis), a leading provider of veterinary point-of-care diagnostic instruments.” 10-K for 2023 | acquisition | in 2018 | — |
Phoenix Central Laboratory for Veterinarians, Inc.Word for word“In 2019, the company acquired Phoenix Central Laboratory for Veterinarians, Inc. and ZNLabs, LLC marking its entry into reference laboratory services and building on a strategy to develop a more comprehensive diagnostics offering with enhanced value for veterinarians.” 10-K for 2023 | acquisition | In 2019 | — |
ZNLabs, LLCWord for word“In 2019, the company acquired Phoenix Central Laboratory for Veterinarians, Inc. and ZNLabs, LLC marking its entry into reference laboratory services and building on a strategy to develop a more comprehensive diagnostics offering with enhanced value for veterinarians.” 10-K for 2023 | acquisition | In 2019 | — |
Ethos Diagnostic ScienceWord for word“In 2020, the company acquired a third veterinary reference lab business, Ethos Diagnostic Science.” 10-K for 2023 | acquisition | In 2020 | — |
Platinum PerformanceWord for word“Zoetis also entered the field of animal nutritionals with the acquisition of Platinum Performance in 2019.” 10-K for 2023 | acquisition | in 2019 | — |
JuroxWord for word“In 2022, the company completed the acquisition of Jurox, an animal health company based in Australia, which brings the company a range of companion animal and livestock products and provides the company with future growth opportunities, manufacturing capacity and increased capabilities in Australia.” 10-K for 2023 | acquisition | In 2022 | — |
BasepawsWord for word“Also in 2022, the company acquired Basepaws, a petcare genetics company that provides pet owners with genetic tests, analytics and early health risk assessments, which help pet owners and veterinarians understand an individual pet’s risk for disease and helps Zoetis identify solutions to complex diseases by informing our research and innovation.” 10-K for 2023 | acquisition | Also in 2022 | — |
PetMedix LtdWord for word“In 2023, the company completed the acquisition of PetMedix Ltd, a privately held research and development stage animal health biopharmaceutical company based in the U.K., which develops antibody-based therapeutics for companion animals.” 10-K for 2023 | acquisition | In 2023 | — |
adivo GmbHWord for word“Also in 2023, the company completed the acquisition of adivo GmbH, a privately held research and development stage animal health biopharmaceutical company based in Germany.” 10-K for 2023 | acquisition | Also in 2023 | — |
Performance Livestock AnalyticsWord for word“Income taxes in Certain significant items also includes: • For 2023, a benefit from the tax loss on the divestiture of Performance Livestock Analytics, partially offset by a tax expense related to changes to prior years’ tax positions with regard to the one-time mandatory deemed repatriation tax under the Tax Cuts and Jobs Act.” 10-K for 2023 | divestiture | For 2023 | — |
majority interest in pet insurance businessWord for word“(d) Primarily represents a net gain on the sale of a majority interest in our pet insurance business.” 10-K for 2023 | divestiture | — | — |
medicated feed additive product portfolio, certain water soluble products and related assetsWord for word“On October 31, 2024, we completed the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets, and, as a result, our major product categories no longer include the category of medicated feed additives.” 10-K for 2024 | divestiture | October 31, 2024 | — |
Abaxis, Inc. (Abaxis)Word for word“Zoetis enhanced the portfolio of its diagnostic products with the acquisition in 2018 of Abaxis, Inc. (Abaxis), a leading provider of veterinary point-of-care diagnostic instruments, including the VetScan ® portfolio of benchtop and handheld diagnostic instruments and consumables.” 10-K for 2024 | acquisition | 2018 | — |
Platinum Performance (Platinum)Word for word“As previously disclosed, we acquired Platinum Performance (Platinum) in August 2019.” 10-K for 2024 | acquisition | August 2019 | — |
majority interest in our pet insurance businessWord for word“For 2023, primarily represents a net gain on the sale of a majority interest in our pet insurance business.” 10-K for 2024 | divestiture | 2023 | — |
Veterinary Pathology GroupWord for word“In 2025, the company acquired Veterinary Pathology Group, a leading veterinary diagnostic laboratory group with multiple locations across the U.K. and Ireland.” 10-K for 2025 | acquisition | In 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) |
|---|---|
| 2016-12-31 | $88 million |
| 2017-12-31 | $0 |
| 2018-12-31 | $1.88 billion |
| 2019-12-31 | $0 |
| 2020-12-31 | $0 |
Deal filings since 2016
- 2025-12-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-08-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-07-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-07-31 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2018-05-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-12-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Zoetis’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-12. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.